High COMMD6 expression is associated with shorter OS and DFS in patients with head and neck squamous cell carcinoma, cholangiocarcinoma and adrenocortical carcinoma, but is associated with longer OS and DFS in patients with low-grade glioma and uveal melanoma [39]. Here, COMMD6 is linked to uveal melanoma.